Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like .046 is the line drawn in the sand for now!
Hence the “in theory”... just as you can’t calculate the decline of the PPS
Because the sooner you do, the faster the debt gets converted.
Or Short and help others get better prices.
You can't calculate market cap with shares that haven't been sold. If note holders are looking to convert all 123 million shares, the pps will decline accordingly. At $0.03, e.g. we are looking at a $7M fully diluted market cap with debt cleared.
Give me a good reason to buy and I will load up.
I highly doubt if anybody associated with delcath was happy settling for the convertible deal, the best way for delcath people to keep their job intact and salary level, was to do it well. It is done warts and all, but the phase 3 is an interesting study I truly want to see the end to
One more unto the breach, dear friends, once more....
Volume on target for 17M today.
123M / 17M / 2 (50% vol max) = approximately 15 trading days, minimum.
My guess is closer to 20 trading days. Puts us around the end of January.
After the note holder has sold the 123M shares at their desire, The SP will be somewhere in the .02 to .05 range.
10Q will be released that states 2017 was not a great year. (no surprise).
Then what?
Where do we go from post January?
MM
Note holders can only sell 50% the collective daily avg (currently 11.5MM) of their pro rata shares until the 15 day holding period. Not until 1/22 (the 15th trading day) can they sell above this restriction. They have access to 123MM aggregate. So yes, in theory the O/S sits at 222MM or market cap of 11MM which is higher than the 28ths closing MK by about 2MM.
Gotta give them credit though for reigning in costs during these difficult times - their Queensbury address certainly looks more humble than a suite in Manhattan! Nice lawns btw!
You are completely wrong in your thinking Sam. It is your opinion though and I respect that. Shareholders who were involved in the r/s were completely wiped out and will never get their money back. There had to be better ways to attract capital than Hudson and DCTH did not have anyone in place to seek out alternative financing. Simpson is protecting her salary and perks as long as she can hold on. That is a simple fact.
It's just short term Trading. The big thing to watch here is how different this company is from just 60 days ago. Debt gone, float has been cleaned up 350-1, REV in Europe, new Director:
Simon Pedder, Ph.D.
Director
Simon Pedder, Ph.D. Dr. Pedder joined the Delcath Board of Directors in November 2017. Dr. Pedder is a scientist and pharmaceutical executive with a 30-year career in drug development. He currently serves as Chief Business and Strategy Officer at Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. During his long career in drug development, Dr. Pedder has held several leadership positions including President and CEO of Cellectar Biosciences, President and CEO of Chelsea Therapeutics, Executive Officer and Vice President of Oncology Pharma Business at Hoffmann-LaRoche, Life Cycle Leader and Global Project Leader of Pegasys/IFN and Head of the Hepatitis Franchise at Hoffmann-LaRoche. Dr. Pedder led the late stage development and commercial launch of multiple proprietary pharmaceutical products, including Pegasys®, Copegus® and Northera®.
It will be fun to see the Shorts scramble when the next PR drops.
Pigs get fed, Hogs get slaughtered.
I still see a buyout here... time will tell.
Churn that volume baby! Get this monkey off our back.
Buyer fatigue....knowing you are at the mercy of the MM. They decide when it goes up...and when it goes down. Only a substantial PR will change that. Green market days mean nothing to the SP of this stock. You just need to buy as low as you can and hope that seller fatigue eventually settles in.
Dreamer . Not on my clock
Here we go back up!
Looks like $0.046 is holding.
Load up!
Thank you sir. This info is very helpful, truly.
Good luck today in the markets.
Truly the end that justifies the means always comes back to personally good trading, it is no fun if one does not seek self improvement
Testing $0.046 for the second time today. If support forms at $0.046, we go back up.
It’s mission to destroy this ticker like I did icld
And those screens will add to the base (as you know; saying it for others). More people who buy in, base continues to grow. Larger the base, more following the stock, more following the stock, larger the benefit to the share price when the co drops positive PRs.
Jenny did what she did to allow the company to survive. It wasn't pretty but the ends justify the means.
Bathroom break...selling isnt over.
Volume lull. Could be a momentum flip. Will be difficult not to sell when it breaks .08 again.
It looks sickeningly sweet for noteholders, but we never know the whole story. One possibility is the warrant situation might turn out a tad better, those warrants 100 percent mystery essentially
I definitely think they have a new batch, the question I have is whether they got it this morning or during the afternoon session yesterday
My god it’s not Clay who controls it all, but OFRI. I never would have guessed it. LoL.
You are so awesome!
Just buy on dips and sell on pops.
https://stocktradingmodel.wordpress.com/
my bet is if anybody large, it will be an entity like Blackrock, but there will be future financing, so this is likely not an opportunity they will jump with both feet on
Hmm..if there was $3 million in debt still to clear as of last week then at an average of $0.045 per share it wouldve taken around 66 million more shares to clear it. Given prices were a little higher recently maybe less. However the recent deal gave noteholders nearly double that amount of shares and $800k?? Sounds like a pretty sweet deal??
Kudos to all short sellers let’s bring this little up bagholders now so we can short more
Everybody buys at .03, Chemostat is approved in the U.S., stock price hits 25 dollars a share and Jen throws a make nice party... Is that all we need? Common Scenario.
The reverse split was actually in your personal best interest, if not you are trying your best to make it in your personal best interest
My other thought is that with 123M shares being dumped into commons...someone has an opportunity to acquire a large stake. I'm not that familiar with voting rights and structure though.
And we are going back up. Load up!
If $0.046 holds, we may go back up.
Sam, there was a video recently of Simpson and the other twat explaining how it was in the best interests of shareholders to approve the reverse split and they had a marketing firm call shareholders to get them to vote. They should be thrown out into the street with no coat.
Bod made the right choice to make Simpson the big chief, that is my opinion.
Who cares
Followers
|
497
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
50157
|
Created
|
05/11/05
|
Type
|
Free
|
Moderators |
In December 2018, Delcath entered into a License Agreement with medac GmbH for the commercialization of the CHEMOSAT® system in Europe. Under the terms of the medac License, medac has the exclusive right to sell and market CHEMOSAT® in all member states of the EU, Norway, Liechtenstein, Switzerland, and the United Kingdom.
Since launching CHEMOSAT® in Europe, over 750 commercial treatments have been performed at over 25 European cancer centers. Physicians in Europe have used CHEMOSAT® to treat patients with a variety of cancers in the liver, primarily ocular melanoma liver metastases, and other tumor types including cutaneous melanoma, hepatocellular carcinoma, cholangiocarcinoma, and liver metastases from colorectal cancer, breast, pancreatic and neuroendocrine.Split # | Date | Ratio |
1 | April 9, 2014 | 1:16 |
2 | July 21, 2016 | 1:16 |
3 | November 6, 2017 | 1:350 |
4 | May 2, 2018 | 1:500 |
5 | December 24, 2019 | 1:700 |
Common Shares Authorized: | 1,000,000,000 |
Common Shares Outstanding: | 70,056 |
Preferred Shares Authorized: | 10,000,000 |
Preferred Shares Outstanding: | 41,447 |
Warrants: | 29 | ($42; exp 2/2020 - 10/2021) |
2019 Warrants: | 1,826,579 | ($23.04; exp 12/2024) |
Options: | 1,640 | |
Total Warrants/Options: | 1,828,248 |
Preferred Stock: | 1,799,093 |
Convertible Notes: | 63,493 |
Total Reserved: | 1,862,586 |
Jennifer K. Simpson, Ph.D. | : 2,965 |
John Purpura, M.S. | : 2,830 |
William D. Rueckert | : 2,619 |
Roger G. Stoll, Ph.D. | : 4,047 |
Marco Taglietti, M.D. | : 2,606 |
Total Shares | : 21,459 |
Altium Capital Management L.P. | : 7,204 |
Rosalind Master Fund L.P. | : 7,024 |
Hudson Bay Master Fund Ltd. | : 7,024 |
Total Shares | : 21,612 |
45 Shareholders (est.) | : 26,985 |
Company Website: Delcath Systems, Inc. | Stock and Financial Website: OTC Marketplace |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |